WEIFANG, Shandong, China, April 29 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (“Shengtai” or “the Company”), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it hosted a conference at the Company’s headquarters to showcase its new state-of-the-art 120,000-ton glucose production facility as well as conducted high-level discussions with key existing customers.
Representatives and officials from over 70 current customers were on hand for the three-day event. Mr. Qingtai Liu, Chairman of Shengtai and other senior members of the Company spoke during the conference as they presented their view on the current operating environment, status of the glucose production facility, as well as high level discussions on strategies that can help the Company to continue to deliver on its promise to provide the highest quality products to end customers. The three-day conference also offered the guests with an opportunity to visit the on-site production facilities. The event provided the Company management with valuable information on customers’ expectations and motivations, and strategic insights into what the Company needs to do to further business development and cooperation with its key customers. Many of whom attended the conference congratulated the Company for consistently delivering high quality products. They also stated they look forward to continuing to work closely with the Company as it is on its way to becoming the top domestic supplier of pharmaceutical grade glucose.
“The activities of this past week not only gave us an opportunity to showcase our state-of-the-art production facilities, our customers were able to gain a better understanding of our operations, production capabilities, and quality control as we develop deeper and more meaningful relationship with many of our key customers,” said Mr. Qingtai Liu, CEO of Shengtai Pharmaceutical, Inc. “In order to compete more effectively in these challenging times, we must continue to show improvement in terms of product development as well as optimize customers overall experience. As one of the leading domestic producers of pharmaceutical grade glucose, we have a responsibility to produce the highest quality products. Our critical health-related products have achieved global quality standards, and our strategic location gives us cost advantage which will benefit our customers by using our products. As we look ahead, the Company is poised to be one of the major beneficiaries from the changing healthcare landscape as a result of the planned government reform.”
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China.
Forward-looking Statements
Certain statements made in this news release, may contain forward-looking statements concerning the Company’s business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, future increases in market demand, possible increases in our market share and predictions and guidance relating to the Company’s future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company’s products, changes to government regulations, risk associated with operation of the Company’s new facilities, risk associated with large-scale implementation of the Company’s business plan, the ability to attract new customers, ability to increase our products’ applications, cost of raw materials, downturns in the Chinese and world economy, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company’s expectations.
CONTACT: Yiru Melody Shi, Chief Financial Officer, Shengtai
Pharmaceutical, Inc. at shengtaicfo@hotmail.com; Or Eddie Cheung, Investor
Relations, Grayling at +1-646-284-9414 or eddie.cheung@us.grayling.com
